SCHEDULE: Iroquois Capital Reports 4.99% Stake in Bionano Genomics

Iroquois Capital Management, LLC, along with Richard Abbe and Kimberly Page, reported a 4.99% beneficial ownership stake in Bionano Genomics, Inc., including shares from warrants subject to ownership blockers.

Summary

• Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page (the "Reporting Persons") collectively reported beneficial ownership of 509,658 shares of Bionano Genomics, Inc. common stock.
• This represents 4.99% of the outstanding common stock of Bionano Genomics, Inc.
• The reported ownership includes 483,183 shares of common stock issuable upon the exercise of warrants.
• These warrants are subject to "Beneficial Ownership Blockers," which prevent exercise if it would result in the holder owning more than 4.99% of the outstanding common stock.
• The filing indicates that Bionano Genomics, Inc. had 9,730,400 shares of Common Stock outstanding as of its Quarterly Report on Form 10-Q filed on November 13, 2025.
• The Reporting Persons certified that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership report (Schedule 13G) indicating a significant, but non-controlling, stake. It does not contain information that would inherently suggest positive or negative sentiment regarding the company's operational or financial performance.

Risks

• The existence of "Beneficial Ownership Blockers" on warrants limits the immediate upside for the reporting persons if the stock price were to rise significantly, as they cannot exceed the 4.99% ownership threshold through warrant exercise.
• The inability to fully exercise warrants due to ownership blockers could impact the reporting persons' flexibility in managing their investment.

Future Outlook

NA

Management Comments

• The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.
• Each of the Reporting Persons disclaim beneficial ownership of these shares, except to the extent of its, his or her pecuniary interest in such shares, if any.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant ownership stake by institutional investors and individuals, which can be viewed as a vote of confidence or a potential influence on future corporate actions, albeit limited by the 4.99% blocker.

Key Dates

Keywords

Bionano Genomics, Iroquois Capital Management, Richard Abbe, Kimberly Page, Schedule 13G, beneficial ownership, common stock, warrants, ownership blockers, SEC filing, BNGO